What is the structural formula of obeticholic acid?

Obeticholic acid (Obeticholic acid) is a farnesoid X receptor (FXR) agonist. Chemically, obeticholic acid is 3α,7α-dihydroxy-6α-ethyl-5β-cholestane-24-acid. It is a white to off-white powder. It is soluble in methanol, acetone and ethyl acetate. Its solubility in water depends on the pH value. Slightly soluble at low pH and easily soluble at high pH. The chemical formula is C26H44O4, and the molecular weight is 420.63g/mol. Obeticholic acid tablets are available in oral dosages of 5mg and 10mg. Each tablet contains as the active ingredient Obeticholic acid and the following inactive ingredients: microcrystalline cellulose, sodium starch glycolate and magnesium stearate.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to obeticholic acid for the treatment of primary biliary cholangitis (formerly known as primary biliary cirrhosis [PBC]), Can be combined with ursodeoxycholic acid (UDCA), a nuclear receptor expressed in the liver and gut that is a key regulator of bile acid, inflammation, fibrosis and metabolic pathways. Physicians will evaluate patients for the presence of decompensated cirrhosis (egChild-Pugh class B or C), a history of decompensated events, or compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, sustained thrombocytopenia), as these conditions are contraindications to use.

During the patient's treatment with obeticholic acid, doctors will routinely monitor the patient's biochemical response to assess tolerance, disease progression and discontinuation needs; they will alsomonitor changes in the patient's blood lipid concentration. For patients who use cholic acid to reduce high-density lipoprotein cholesterol concentration, they will evaluate their response to treatment after 1 year to evaluate whether to continue treatment.